GlassScriptPhysician profile
Maria Cortes
NPI 1730473414
$979.42
in general payments reported to CMS, 2019-2025
14 companies · $65.70 in 2025
The $65.70 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $347 · 2023: $418 · 2024: $149 · 2025: $65.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.84 |
| Education | $180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $310.34 | 2022-2023 | Enhertu |
| Astellas Pharma US INC | $224.70 | 2022-2025 | Cresemba |
| Sanofi-Aventis U.S. LLC | $198.13 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $48.96 | 2023 | Imfinzi |
| Merck Sharp & Dohme LLC | $36.91 | 2023-2024 | Keytruda |
| Medtronic, INC. | $31.40 | 2023 | Minimed 780g |
| Blueprint Medicines Corporation | $20.74 | 2023 | Ayvakit |
| Incyte Corporation | $18.47 | 2025 | Monjuvi, Zynyz |
| Taiho Oncology, INC. | $17.08 | 2024 | |
| Abbvie INC. | $16.53 | 2025 | |
| Emd Serono, INC. | $14.88 | 2023 | Tepmetko |
| Cumberland Pharmaceuticals, INC. | $14.35 | 2024 | Sancuso |
| Eisai INC. | $14.22 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.71 | 2023 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Cortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.